• Explore /
  • Poster
  • / SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).

SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).

Abstract Poster

Authors

null

Alain Patrick Algazi

University of California, San Francisco Medical Center- Mt. Zion, San Francisco, CA

Alain Patrick Algazi , James Moon , Bartosz Chmielowski , Roger Lo , Kari Lynn Kendra , Christopher D. Lao , Karl D. Lewis , Rene Gonzalez , Kevin Kim , John E. Godwin , Brendan D. Curti , Megan Othus , Antoni Ribas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT01902173

Citation

J Clin Oncol 35, 2017 (suppl; abstr 2578)

DOI

10.1200/JCO.2017.35.15_suppl.2578

Abstract #

2578

Poster Bd #

70

Abstract Disclosures

Similar Posters

First Author: Makoto Tahara

First Author: Lisa Zimmer

First Author: Birgit Geoerger

First Author: Reinhard Dummer